Samina is a Biotech Executive & Strategic Advisor with a distinguished track record of value creation through notable acquisitions within the biopharmaceutical industry worth over $40B. Samina partners with CEOs and boards of companies at various stages of transition, whether private, public or IPO-ready and from early-stage to commercialization. She has strong operational experience, a governance/compliance mindset, fiduciary stewardship, and DE&I leadership.
Samina has 30+ years of success in delivering outcome- and analytics-driven results in complex and competitive businesses. With expertise in company transformation and exit preparation, she reframes investment theses to influence and increase value perception. She is a seasoned company officer and was an Executive Team member at NASDAQ: AIMT, NASDAQ: AXON, and NASDAQ: PCYC. She is certified in corporate board governance and is actively seeking board opportunities
Integrations are incredibly destabilizing and stressful for impacted employees, as well as for those who “survive.” Organizations that are worth acquiring are successful and attractive because they are comprised of smart, talented people who have created that success.
Many (not all) physician-/scientist-CEOs have a tendency to revert to their area of comfort by using highly scientific terminology and concepts in ways that derail from the purpose of the presentation: articulating the business case in a finite amount of meeting time.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.